Takeda

Since launching in 2024, our program with Partners In Health has provided professional development and mentorship to more than 1,300 nursing students, nurses and midwives across Malawi, Rwanda, Lesotho, Liberia, Sierra Leone, Haiti, Mexico and Peru – and we’re just getting started. By breaking down financial and educational barriers, we’re helping future nurse leaders like Moinya Lukulay turn ambition into action and bring quality care where it’s needed most because in many communities, nurses are often the first and only contact patients have with the health care system. Get the full story: https://lnkd.in/ey2KYcAH #HealthEquity #CSR #OurStories

The VERDICT study team and principal investigator, Vipul Jairath, are excited to announce that 95% of the participants have completed the study! We thank the patients and caregivers, investigators, and site study teams for their support in achieving this exciting milestone and look forward to sharing results from this study soon. The VERDICT study aims to determine the optimal treatment target for assessing disease activity and response to therapy in ulcerative colitis, which is a research priority for disease management. Results will inform clinical practice, regulatory endpoints, and targets for drug development. VERDICT is a collaborative study between Alimentiv and Takeda and a testament to the dedication of both organizations to improve the lives of patients living with IBD.

Psoriasis can have a major impact on quality of life, especially when psoriasis plaques are on highly visible areas such as the face, scalp and hands. That’s why a disease severity classification system that considers quality of life is so important. Takeda recognizes the work of the International Psoriasis Council, the National Psoriasis Foundation and the American Academy of Dermatology to advance standardized, patient centered definitions of disease severity, so the true impact of the disease is reflected. https://lnkd.in/ecN2G5HF Read the story to find out more. #OurStories

We are thrilled to announce the return of the Dengue Academy Masterclass Series happening from 11 February to 11 March 2026! This year, as part of our commitment to accessibility, we've introduced live translation in 30 languages so participants can select their preferred language to follow and engage with the sessions. Join three expert-led, live, virtual sessions designed for healthcare professionals worldwide. Agenda: 11 February: – Rising Dengue, Rising Priority: Managing the Growing Clinical Burden • Global epidemiology update for 2025 and resurgence in non-endemic areas  • Practical case-based management approaches and common errors   25 February: – Dengue and the Traveler: Risk, Prevention, and Standard Clinical Guidance  • Risk profiles and tailoring prevention advice  • Differential diagnosis and diagnostics timing   11 March: – The Future of Dengue Control: Innovations, Insights, and Impact • AI-driven early warning systems and integrated strategies  • Latest vaccine landscape and real-world data   Registration is free and open now! https://lnkd.in/ehi7CTdW   #Dengue #DengueFever #DengueAcademy #MedicalEducation #GlobalHealth #InfectiousDiseases   *This non-promotional series is organized and funded by Takeda Pharmaceuticals International AG, including the payment of external speakers as consultants. Events are intended for healthcare professionals outside of the US and UK and not for members of the general public. ©2026 Takeda Pharmaceuticals International AG. All rights reserved. Takeda and the Takeda logo are registered trademarks of Takeda Pharmaceutical Company Limited. All other trademarks are the property of their respective owners.

Why Takeda? Here’s what colleagues have to say. Across roles, regions and career stages, teams share a commitment to patients, strong values and meaningful work. These voices reflect the culture that continues to shape what comes next. Which part of this culture resonates most with you? Tell us in the comments. #TeamTakeda #MakeHistoryChangeFutures #BioPharmaHiring #NowHiring

We’re thrilled to announce the shortlisted finalists for the 2026 Innovators in Science Award, presented in partnership with Nature Portfolio. Nine outstanding early-career researchers were selected from a record-breaking pool of global submissions, and their work spans some of the most exciting frontiers in Gastrointestinal & Inflammatory Diseases, Neuroscience and Oncology. Through this award we’re committed to providing these innovators with the recognition, resources and support they need to push the boundaries of science. Meet the finalists here https://lnkd.in/eJBwYhqg

The daily realities of living with psoriasis can be complex – impacting an individual’s physical, emotional and psychological wellbeing. Through collaboration and an unwavering focus on innovation, we aim to drive progress for the psoriatic disease community that we serve. Hear more from Warren Winkelman.

Early-career scientists need more than funding—they need visibility and support. Dr. Shruti Naik of Icahn School of Medicine at Mount Sinai, an Innovators in Science award winner, is studying how tissues remember inflammation and how to reprogram them for long-term health. Read the story to learn how this program helps scientists tackle big questions early in their careers. #OurStories https://lnkd.in/e-e2mCtn

We recently asked a simple question: who or what inspires you in your career journey? Heather Dean, Senior Vice President, shared a powerful reflection on her why and the purpose that continues to guide her work. Her response is a reminder that meaningful careers are often shaped by personal motivation, values and the impact we hope to make. #TeamTakeda #MakeHistoryChangeFutures #BioPharmaHiring #NowHiring

Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is a rare, life-threatening blood disorder caused by a severe deficiency in the ADAMTS13 enzyme. It can lead to the formation of small clots in blood vessels throughout the body, potentially triggering acute events such as stroke, heart attack or pulmonary embolism. The wide range of symptoms and experiences can make it difficult to recognize and manage. Learn more as Lucas shares his journey with iTTP: https://lnkd.in/eeEwhHJB